These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7704180)

  • 1. Is universal neonatal hemoglobinopathy screening cost-effective?
    Bergman AB
    Arch Pediatr Adolesc Med; 1995 Apr; 149(4):466-7. PubMed ID: 7704180
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of neonatal screening for sickle cell disease.
    Lane PA; Eckman JR
    J Pediatr; 1992 Jan; 120(1):162-3. PubMed ID: 1731017
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of preoperative screening for sickle cell disease in a population with a newborn screening program: a cohort study.
    O'Leary JD; Odame I; Pehora C; Chakraborty P; Crawford MW
    Can J Anaesth; 2013 Jan; 60(1):54-9. PubMed ID: 23104576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness evaluation of newborn hemoglobinopathy screening from the perspective of state health care systems.
    Gessner BD; Teutsch SM; Shaffer PA
    Early Hum Dev; 1996 Jul; 45(3):257-75. PubMed ID: 8855399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research.
    Davies SC; Cronin E; Gill M; Greengross P; Hickman M; Normand C
    Health Technol Assess; 2000; 4(3):i-v, 1-99. PubMed ID: 10840658
    [No Abstract]   [Full Text] [Related]  

  • 6. Sickle cell trait/hereditary persistence of fetal hemoglobin trait. Misdiagnosis as sickle cell anemia by newborn screening.
    Rubin EM; Rowley PT
    Am J Dis Child; 1979 Dec; 133(12):1248-50. PubMed ID: 517474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is universal neonatal hemoglobinopathy screening cost-effective?
    Sprinkle RH; Hynes DM; Konrad TR
    Arch Pediatr Adolesc Med; 1994 May; 148(5):461-9. PubMed ID: 8180635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique.
    Grosse SD; Olney RS; Baily MA
    Appl Health Econ Health Policy; 2005; 4(4):239-47. PubMed ID: 16466275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Communication of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states.
    Kavanagh PL; Wang CJ; Therrell BL; Sprinz PG; Bauchner H
    Am J Med Genet C Semin Med Genet; 2008 Feb; 148C(1):15-22. PubMed ID: 18200513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parental receptivity to neonatal sickle trait identification.
    Rowley PT
    Pediatrics; 1989 May; 83(5 Pt 2):891-3. PubMed ID: 2717323
    [No Abstract]   [Full Text] [Related]  

  • 11. A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola.
    McGann PT; Grosse SD; Santos B; de Oliveira V; Bernardino L; Kassebaum NJ; Ware RE; Airewele GE
    J Pediatr; 2015 Dec; 167(6):1314-9. PubMed ID: 26477868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newborn hemoglobinopathy screening.
    Abildgaard CF; Winston C
    West J Med; 1990 Dec; 153(6):651. PubMed ID: 2293477
    [No Abstract]   [Full Text] [Related]  

  • 13. [Recognition of children with sickle cell disease in The Netherlands].
    Heijboer H; Van den Tweel XW; Fijnvandraat K; Peters M
    Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2498-501. PubMed ID: 18062592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis.
    Panepinto JA; Magid D; Rewers MJ; Lane PA
    J Pediatr; 2000 Feb; 136(2):201-8. PubMed ID: 10657826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal screening for sickle cell disease: a cost-effectiveness analysis.
    Tsevat J; Wong JB; Pauker SG; Steinberg MH
    J Pediatr; 1991 Apr; 118(4 Pt 1):546-54. PubMed ID: 1901081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014-2019.
    Hernandez AG; Kiyaga C; Howard TA; Ssewanyana I; Ndeezi G; Aceng JR; Ware RE
    Trop Med Int Health; 2021 Jan; 26(1):23-32. PubMed ID: 33151598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening.
    Kunz JB; Awad S; Happich M; Muckenthaler L; Lindner M; Gramer G; Okun JG; Hoffmann GF; Bruckner T; Muckenthaler MU; Kulozik AE
    Ann Hematol; 2016 Feb; 95(3):397-402. PubMed ID: 26658910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated incidence of sickle-cell disease in Aruba and St. Maarten suggests cost-effectiveness of a universal screening programme for St. Maarten.
    van Heyningen AM; Levenston MJ; Tamminga N; Scoop-Martijn EG; Wever RM; Verhagen AA; van der Dijs FP; Dijck-Brouwer DA; Offriinga PJ; Muskiet FA
    West Indian Med J; 2009 Sep; 58(4):301-4. PubMed ID: 20099768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MALDI-TOF MS profiling as the first-tier screen for sickle cell disease in neonates: matching throughput to objectives.
    Hachani J; Duban-Deweer S; Pottiez G; Renom G; Flahaut C; Périni JM
    Proteomics Clin Appl; 2011 Aug; 5(7-8):405-14. PubMed ID: 21751410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of neonatal screening for sickle cell disorders on lifetime treatment costs and early deaths avoided: a modelling approach.
    Karnon J; Zeuner D; Ades AE; Efimba W; Brown J; Yardumian A
    J Public Health Med; 2000 Dec; 22(4):500-11. PubMed ID: 11192278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.